The incidence of hs-TnT/NT-proBNP elevations at 6, 12, and 24 months.
Cumulative incidences and 95% confidence intervals, considering death as a competing event.
The incidence of hs-TnT/NT-proBNP elevations at baseline, 3, 6, 12, and 24 months.
Cumulative incidences and 95% confidence intervals, considering death as a competing event.
Evolution of hs-TnT/NT-proBNP in 24 months compared to baseline.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Evolution of transthoracic 3D echocardiography parameters (dimensions, diastolic function, valvular abnormalities, LVEF, strain analysis) at baseline, 3, 6, 12, and 24 months.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Evolution of electrocardiography parameters (rhythm, heart axis, PQ interval, QRS duration, bundle branch block, QT interval, RR interval, pathological Q's, left ventricular hypertrophy and STT segments) at baseline, 3, 6, 12, and 24 months.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Association between the evolution of troponin/NT-proBNP and transthoracic echocardiography parameters at baseline, 3, 6, 12, and 24 months.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Association between the evolution of troponin/NT-proBNP and electrocardiography (rhythm, heart axis, PQ, QRS, bundle branch block, QT, RR, pathological Q's, left ventricular hypertrophy and STT segments) parameters at baseline, 3, 6, 12, and 24 months.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Cumulative incidence of cardiovascular (CV) abnormalities at 3, 6, 12, and 24 months based on the CARDIOTOX classification system of Sendón et al., with the inclusion of pericardial effusion and new arrhythmias.
Cumulative incidences and 95% confidence intervals, considering death as a competing event.
Association between the evolution of troponin/NT-proBNP and CV abnormalities (as classified based on the CARDIOTOX classification for myocardial injury including cardiac biomarkers, symptoms, LVEF, LA area, LVESV, GLS and diastolic function).
Joint model combining a linear mixed model for troponin and a sub-distributional proportional hazards model for the time-to-event taking into account death as a competing event for CV abnormality and MACE.
Cumulative incidence of MACEs at 3, 6, 12, and 24 months. MACEs were defined as the composite outcome of nonfatal stroke, nonfatal myocardial infarction, hospital admission for heart failure (HF) and cardiac revascularization, and CV death.
Cumulative incidences and 95% confidence intervals, considering death as a competing event.
Overall survival.
Cumulative incidences and 95% confidence intervals
Association between the evolution of troponin/NT-proBNP and MACEs over a period of two years. Nonfatal stroke, nonfatal myocardial infarction, hospital admission for heart failure, cardiac revascularization and CV death will be combined to report MACEs.
Joint model combining a linear mixed model for troponin and a sub-distributional proportional hazards model for the time-to-event taking into account death as a competing event for CV abnormality and MACE.
The difference in the evolution of hs-TnT/NT-proBNP between combination therapy and monotherapy over a period of two years.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
The difference in the evolution of transthoracic echocardiography parameters (dimensions, diastolic function, valvular abnormalities, LVEF, strain analysis) between combination therapy and monotherapy over a period of two years.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
The difference in the evolution of electrocardiography parameters (rhythm, heart axis, PQ, QRS, bundle branch block, QT, RR, pathological Q's, left ventricular hypertrophy and STT segments) between combination therapy and monotherapy.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Association between patient characteristics (demographics, medical history, current oncological disease, prior cancer history, prior/concomitant medication and other relevant parameters) and troponin.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Association between patient characteristics (demographics, medical history, current oncological disease, prior cancer history, prior/concomitant medication and other relevant parameters) and NT-proBNP.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Agreement between hs-TnT and hs-TnI levels at baseline, 3, 6, 12, and 24 months.
Bland-Altman curves and intraclass correlation coefficient (ICC) based on a two-way mixed effects model. The ICC and 95% confidence interval will be reported.
The proportion of severe immune-related non-CV toxicities (grades 3-5).
Proportions and 95% confidence interval
Association between the evolution of troponin/NT-proBNP and severe immune-related non-CV toxicities (grades 3-5, e.g. pneumonitis, colitis, thyroiditis, etc. according to the CTCAE criteria).
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Association between the evolution of troponin/NT-proBNP and overall survival.
Joint model combining a linear mixed model for troponin and a sub-distributional proportional hazards model for the time-to-event taking into account death as a competing event for CV abnormality and MACE.
Association between the evolution of troponin and diastolic function (based on the recommendations listed in https://doi.org/10.1016/j.echo.2016.01.011, mitral inflow, tissue doppler imaging parameters).
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Calcium score at baseline, 12 months, and 24 months.
Proportions and 95% confidence interval
Peripheral vascular function at baseline, 3 months, 6 months, 12 months and 24 months.
Flow mediated dilatation: dilatation % from baseline to maximal post-occlusion diameter.
Peripheral arterial tonometry ratio: based on the response to reactive hyperemia using post and pre-occlusion values
Association between the evolution of troponin and calcium score.
Flow mediated dilatation: dilatation % from baseline to maximal post-occlusion diameter.
Peripheral arterial tonometry ratio: based on the response to reactive hyperemia using post and pre-occlusion values